Latest by Richard Jefferys

Keeping an Eye on Intellectual Property Issues in HIV Cure and Prevention Research

"As exemplified by the AZT protests, advocates have long pointed out the injustice of excessive, access-limiting profiteering on treatments developed with public support."

By Richard Jefferys for Treatment Action Group

Combining Broadly Neutralizing Antibodies Shows Promise

Results from the first human trials of a dual broadly neutralizing antibodies regimen appeared effective, safe, and well tolerated.

By Richard Jefferys for Treatment Action Group

Post-AIDS 2018 Updates on HIV Cure Research

In the aftermath of the 22nd International AIDS Conference (AIDS 2018), there has been some reflecting on the challenges facing the HIV cure research field.

By Richard Jefferys for Treatment Action Group

Studying HIV Persistence in Liver Macrophages

Invesitgators sought to determine whether human liver macrophages can sequester infectious HIV in people on antiretroviral therapy.

By Richard Jefferys for Treatment Action Group

The Role of Vaccines and Cures in HIV Elimination

Even a moderately efficacious HIV vaccine could make a significant additional contribution to halting the virus. And for HIV-positive people, a true end to HIV lies not in an epidemiological calculus, but in a cure.

By Richard Jefferys for Treatment Action Group

Elite Controllers: Sex Differences and Factors Associated With Loss of Immune Control

The ability of elite controllers to maintain undetectable viral loads and relatively preserved CD4 T-cell counts in the absence of antiretroviral therapy has led them to be proposed as a model for a functional cure of HIV infection.

By Richard Jefferys for Treatment Action Group

Assessing Antiretroviral Therapy Interruptions in HIV Cure Research

During a clinical trial of the broadly neutralizing antibody VRC01, study results offered reassurance that treatment interruption had no long-term negative effects for participants -- but there are some possible safety concerns that the data does not...

By Richard Jefferys for Treatment Action Group

Recruiting Natural Killer Cells to Target HIV Persistence

There is growing interest in cells considered part of the innate immune system, particularly natural killer (NK) cells. A number of studies have been published that support the idea that NK cells can play an important role in controlling virus replic...

By Richard Jefferys for Treatment Action Group

New Data on Identifying and Targeting the Latent HIV Reservoir

Several recently presented and published studies offer potentially important new data relevant to efforts to identify cells containing latent HIV and target them for elimination.

By Richard Jefferys for Treatment Action Group

Gene Therapy in HIV Cure Research

There is a great deal of interest in exploring the potential of gene therapy to cure HIV and multiple gene therapy strategies are under investigation.

By Richard Jefferys for Positively Aware